Alpenglow Biosciences, Inc.
Seattle, WA
- UEI
- DVN2AF9A1YV3
- CAGE
- 8BCQ7
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2121 N 35th St #100, Seattle, WA 98103, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Washington | D24AC00357 | $1,207,399 | |
| University Of Washington | D24AC00357 | $1,758,752 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Quantitative Imaging Systems LLC | Pittsburgh, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Numentus Technologies Inc. | Menlo Park, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Surgivance Inc. | New York, NY | — |
| Collagen Medical LLC | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Creatv Microtech Inc. | Potomac, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Alpenglow Biosciences, Inc. is a for-profit biotechnology company that provides research and development services focused on advancing diagnostic techniques in disease areas like cancer, diabetes, and digestive and kidney diseases. Through past federal grants, the company has developed platforms to enable rapid imaging and analysis of clinical tissue samples, with a focus on applying open-top light-sheet microscopy and machine learning to improve disease diagnosis.
Specific services provided through federal grants have included: developing multiplex staining protocols and machine learning pipelines for evaluating disease markers in rectal biopsies, liver biopsies, prostate biopsies, and breast cancer biopsies; optimizing open-top light-sheet microscopy imaging and computational pathology techniques to enable same-day breast cancer diagnosis from core needle biopsies; and pioneering the application of 3D microscopy and AI-based tissue analysis to improve disease screening, prognosis, and personalized medicine. Major federal funding has come from the National Institutes of Health's National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and other agencies under project grants supporting extramural research relevant to agency missions.
Quick answers
Is Alpenglow Biosciences, Inc. registered in SAM.gov?
Yes. Alpenglow Biosciences, Inc.'s SAM.gov registration is active through March 13, 2027.
What is Alpenglow Biosciences, Inc.'s CAGE code?
Alpenglow Biosciences, Inc.'s CAGE code is 8BCQ7, and its Unique Entity ID (UEI) is DVN2AF9A1YV3.
What is Alpenglow Biosciences, Inc.'s most recent federal award?
Alpenglow Biosciences, Inc.'s most recent federal grant award is 3D diagnosis of hirschsprung disease using open-top light-sheet microscopy (R43DK133083), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on April 1, 2022.
On GovTribe
See Alpenglow Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors